These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 23142648)

  • 1. Does Paricalcitol (Zemplar®) interfere with 1,25-dihydroxyvitamin D measurement by liquid chromatography-tandem mass spectrometry assays?
    El-Khoury JM; Bicer F; Bunch DR; Yuan C; Wang S
    Clin Chim Acta; 2013 Jan; 415():230-2. PubMed ID: 23142648
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal interference from paricalcitol (Zemplar®) in underivatized 1,25-dihydroxyvitamin D LC-MS/MS assays.
    Pauwels S; Rozenski J; Jans I; Billen J; Vanderschueren D; Vermeersch P
    Clin Chim Acta; 2014 Feb; 429():104-5. PubMed ID: 24326126
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
    Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
    J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technical and clinical evaluation of the VITROS® Immunodiagnostic Products 25-OH Vitamin D Total Assay--comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method.
    Cavalier E; Rousselle O; Ferrante N; Carlisi A; Le Goff C; Souberbielle JC
    Clin Chem Lab Med; 2013 Oct; 51(10):1983-9. PubMed ID: 23732682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of 1,25-dihydroxyvitamin D2 in rat serum using liquid chromatography with tandem mass spectrometry.
    Sudsakorn S; Phatarphekar A; O'Shea T; Liu H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jan; 879(2):139-45. PubMed ID: 21168373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-clinical response analysis of paricalcitol in patients with chronic kidney disease (stage 5) on hemodialysis or peritoneal dialysis.
    Noertersheuser PA; Pradhan RS; Klein CE; Williams LA; Palaparthy R; Garimella TS; Lichtenberger O; Awni WM
    J Clin Pharmacol; 2012 Aug; 52(8):1162-73. PubMed ID: 21940716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paricalcitol and cardiorenal outcome: from the IMPACT study to clinical practice.
    Bellasi A; Galassi A; Salvi P; Cozzolino M
    Blood Purif; 2013; 36(1):12-6. PubMed ID: 23736115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised clinical study of alfacalcidol and paricalcitol.
    Hansen D
    Dan Med J; 2012 Feb; 59(2):B4400. PubMed ID: 22293059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
    Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
    Al-Baaj F; Yadav P; Al-Rifai A
    J Ren Care; 2011 Jun; 37(2):75-9. PubMed ID: 21561542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.
    Hansen D; Rasmussen K; Pedersen SM; Rasmussen LM; Brandi L
    Nephrol Dial Transplant; 2012 Jun; 27(6):2263-9. PubMed ID: 22140123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
    Cozzolino M; Brancaccio D
    Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the presence of 3-epi-25OHD3 affect the routine measurement of vitamin D using liquid chromatography tandem mass spectrometry?
    Keevil B
    Clin Chem Lab Med; 2011 Oct; 50(1):181-3. PubMed ID: 22011227
    [No Abstract]   [Full Text] [Related]  

  • 15. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vitamine D in patients with osteoporosis: sufficient or necessary?].
    Ferrari S
    Rev Med Suisse; 2007 Jun; 3(115):1515-6, 1518-20. PubMed ID: 17682795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
    Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
    Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
    [No Abstract]   [Full Text] [Related]  

  • 18. [Role of paracalcitol in the management of non-dialysis CKD: state of art and... Unmet needs].
    Mascia S; Garofalo C; Donnarumma G; Di Pietro R; Liberti ME; Pacilio M; Sagliocca A; Zamboli P; Minutolo R; Conte G; De Nicola L
    G Ital Nefrol; 2010; 27(6):616-28. PubMed ID: 21132644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in clinical vitamin D status by DiaSorin Liaison and LC-MS/MS in the presence of elevated 25-OH vitamin D2.
    de Koning L; Al-Turkmani MR; Berg AH; Shkreta A; Law T; Kellogg MD
    Clin Chim Acta; 2013 Jan; 415():54-8. PubMed ID: 22975531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of 1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) in human serum.
    El-Khoury JM; Wang S
    Clin Biochem; 2012 Jun; 45(9):707-8. PubMed ID: 22465273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.